National Bank of Canada FI Has $161.14 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Key Points

• National Bank of Canada FI increased its stake in Gilead by 12.8% in Q3 to 1,451,694 shares, worth about $161.14 million (0.12% of the company) at the end of the reporting period.
• Gilead beat quarterly expectations with $1.86 EPS on $7.93 billion in revenue and set FY2026 guidance of $8.45–$8.85 EPS; the company also raised its quarterly dividend to $0.82 (annualized $3.28, ~2.3% yield).
• Analyst coverage is broadly positive with a consensus rating of "Moderate Buy" and an average price target of about $157.62, while several firms (e.g., Morgan Stanley, BofA) have recently raised targets.

National Bank of Canada FI lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 12.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,451,694 shares of the biopharmaceutical company's stock after purchasing an additional 164,182 shares during the quarter. National Bank of Canada FI owned 0.12% of Gilead Sciences worth $161,137,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Csenge Advisory Group grew its holdings in shares of Gilead Sciences by 319.0% during the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company's stock worth $2,375,000 after purchasing an additional 16,288 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in shares of Gilead Sciences by 52.1% in the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company's stock valued at $8,713,000 after buying an additional 26,882 shares during the last quarter. Cookson Peirce & Co. Inc. lifted its position in Gilead Sciences by 249.1% during the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company's stock worth $1,115,000 after buying an additional 7,168 shares in the last quarter. Railway Pension Investments Ltd lifted its position in Gilead Sciences by 3.1% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company's stock worth $157,139,000 after buying an additional 42,200 shares in the last quarter. Finally, TriaGen Wealth Management LLC bought a new stake in Gilead Sciences during the 3rd quarter worth about $1,274,000. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on GILD shares. Weiss Ratings restated a "buy (b)" rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. Bank of America set a $162.00 price target on shares of Gilead Sciences and gave the company a "buy" rating in a research note on Wednesday, February 11th. Morgan Stanley raised their price target on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an "overweight" rating in a report on Wednesday, February 11th. HSBC boosted their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a "hold" rating in a research report on Wednesday, December 10th. Finally, Wolfe Research upped their price objective on Gilead Sciences from $155.00 to $170.00 and gave the stock an "outperform" rating in a report on Thursday, February 12th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $157.62.

Gilead Sciences Price Performance

Shares of GILD stock opened at $145.21 on Tuesday. The firm's 50 day moving average price is $141.16 and its two-hundred day moving average price is $127.19. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The stock has a market cap of $180.27 billion, a PE ratio of 21.45, a PEG ratio of 1.90 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to analysts' expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a $0.82 dividend. This is a boost from Gilead Sciences's previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Friday, March 13th. Gilead Sciences's dividend payout ratio is currently 48.45%.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the transaction, the chief financial officer directly owned 167,779 shares in the company, valued at approximately $25,910,110.97. The trade was a 1.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel Patrick O'day sold 115,640 shares of the company's stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares of the company's stock, valued at approximately $76,504,230. This trade represents a 16.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 303,280 shares of company stock worth $43,203,470. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.